Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210
23 août 2023 06h00 HE
|
Bionomics Ltd
The last patient last visit has been completed in the Phase 2b ATTUNE study of BNC210 for the treatment of PTSDTopline results from Phase 2b ATTUNE study of BNC210 in patients with PTSD are expected...
Quarterly Activities and Cashflow Report
31 juil. 2023 06h00 HE
|
Bionomics Ltd
ADELAIDE, Australia, and CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO), (Bionomics or the Company) a clinical-stage biopharmaceutical company...
Bionomics Announces Intention to Delist from the Australian Securities Exchange (ASX)
25 juil. 2023 06h00 HE
|
Bionomics Ltd
ADELAIDE, Australia and CAMBRIDGE, Mass., July 25, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO, NASDAQ:BNOX) (Bionomics or the Company) a clinical-stage biotechnology company developing...
Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth
03 juil. 2023 06h00 HE
|
Bionomics Ltd
Alan Fisher appointed Chair of the Board of DirectorsTim Cunningham joins as Chief Financial Officer ADELAIDE, Australia and CAMBRIDGE, Mass., July 03, 2023 (GLOBE NEWSWIRE) -- Bionomics...
Bionomics to Present at Upcoming June Investor Conferences
15 juin 2023 08h00 HE
|
Bionomics Ltd
ADELAIDE, Australia and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biotechnology company developing...
Bionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
30 mai 2023 06h00 HE
|
Bionomics Ltd
ADELAIDE, Australia and CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company...
Quarterly Activities and Cashflow Report
28 avr. 2023 06h00 HE
|
Bionomics Ltd
ADELAIDE, Australia, April 28, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO,), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel,...
Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
27 avr. 2023 06h00 HE
|
Bionomics Ltd
ADELAIDE, Australia, April 27, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel allosteric ion...
Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)
08 mars 2023 19h00 HE
|
Bionomics Ltd
Both doses of BNC210 as an acute treatment resulted in reductions in anxiety across multiple phases of the public speaking challengeResults achieved statistical significance in post-hoc analysis of...
Bionomics’ Half-Year Report
23 févr. 2023 06h00 HE
|
Bionomics Ltd
ADELAIDE, Australia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, NASDAQ: BNOX), today announced its FY2023 report for the half-year ended 31 December 2022. This period represented...